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Several forms of prenatal screening and diagnostic testing are available that can provide 
information about the likelihood of a genetic or chromosomal condition in pregnancy. Each of 
the available technologies entail unique benefits and limitations, and patient comprehension of 
the differences among these tests is crucial to uphold the principle of informed consent. The 
primary research goal of our study was to establish what women recall of the benefits, risks, and 
limitations of the prenatal aneuploidy screening they were offered as a part of their prenatal care 
by their medical provider. A total of 349 women were surveyed and 182 met eligibility criteria 
having had a recent or third-trimester pregnancy. Overall knowledge scores for participants 
ranged from 0 to 82.9 out of 100, with an average score of 32.8 (SD = 21.9). We found 
significantly higher scores in women who were offered testing by genetic professionals, met with 
a genetic counselor in prior pregnancies, were 35-years or older, or were given the choice of both 
screening and diagnostic tests. Our data support the importance of a thorough informed consent 
when discussing prenatal aneuploidy testing with patients.  
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According to practice guidelines from the American College of Obstetricians & 
Gynecologists (ACOG), prenatal testing should be made available to all women who wish to 
determine the risks of having a child with certain birth defects or genetic conditions (Rose & 
Mercer, 2016). Aneuploidy, or the condition of having more or less than the normal complement 
of chromosomal material, is among the most commonly tested-for conditions. Several forms of 
prenatal screening and diagnostic testing are available that detect aneuploidy or the risk of 
aneuploidy, and each of these technologies has unique benefits and limitations. Because of the 
complexities involved with prenatal testing, several organizations, including ACOG, the 
American College of Medical Genetics and Genomics (ACMG), and the National Society of 
Genetic Counselors (NSGC), have published guidelines regarding testing for aneuploidy in 
pregnancy. All of these professional guidelines stress the importance of informed consent prior 
to initiating testing (Gregg et al., 2016; Rose & Mercer, 2016; Wilson et al., 2013). This includes 
a discussion of the risks, benefits, and limitations of each test, as well as a consideration of the 
patient’s clinical circumstances, values, and preferences. However, it is not clear to what extent 
this requirement for informed decision-making is being met in practice. 
Analyte screening, ultrasound, and non-invasive prenatal screening (NIPS) are among the 
tools used to screen for aneuploidy, and a major point of comparison between these modalities 
has been the clinical validity of the screening tests. Since its introduction in 2011, NIPS has been 
shown to have the highest detection rate for Down syndrome and lowest false positive rate for 
traditional aneuploidies relative to other screening methodologies (Pergament et al., 2014; 
Taneja et al., 2016). Despite this advantage, NIPS is not the most effective test for all purposes. 
For example, NIPS does not assess the risk of neural tube defects and overall may be less likely 
to detect other genetic and chromosomal conditions than analyte screening (Baer et al., 2015; 
Norton, Jelliffe-Pawlowski, & Currier, 2014; Shaffer & Norton, 2018). Given that common 
aneuploidies make up a lower fraction of the total risk in younger women, there has been some 
suggestion that analyte screening is more likely to lead to diagnosis of a clinically significant 
condition than NIPS in many women. Similarly, fetal ultrasound is useful in detecting structural 
anomalies and soft markers that may indicate an increased risk for aneuploidy as well as other 
genetic conditions. 
Diagnostic tests are also available in the form of chorionic villi sampling (CVS) and 
amniocentesis which determine, with as much certainty as possible, whether the fetus is 
aneuploid. Both diagnostic tests allow for further genetic studies beyond those for aneuploidy, 
including, but not limited to, single gene testing and chromosomal microarray. CVS allows for 
early diagnosis of the fetus by testing cells directly from the placenta. However, in 2% of viable 
pregnancies, chromosomal abnormalities exist and are confined to the placenta, which may result 
in the misdiagnosis of an unaffected fetus (Kalousek & Vekemans, 1996). Amniocentesis 
remains the gold standard for diagnosing aneuploidy, as it directly tests fetal cells in the amniotic 
fluid. Other advantages of amniocentesis include the testing for neural tube defects, and fetal 
infections. Due to the invasive nature of both procedures, they carry a small risk of miscarriage 
due to infections or amniotic sac rupture, generally quoted as less than 1% (Choudry, Masood, & 
Ahmed, 2012; Eddleman et al., 2006; Tabor et al., 1988). 
Despite the emphasis on informed consent prior to prenatal aneuploidy testing, not all 
patients receive adequate counseling. Many factors have been found to influence uptake of 
aneuploidy screening including education level, income, experience with genetic testing, 
willingness to consider abortion, and experience with disability (Sayres, Allyse, Goodspeed, & 
Cho, 2014). Women also report considering multiple factors when deciding if and how to pursue 
prenatal aneuploidy testing including accuracy, safety, timing, and ease of testing (Lewis, Hill, & 
Chitty, 2016). Concerns have been raised regarding the impact of routinization on patient choice 
in initiation of testing (Allyse, Sayres, Goodspeed, & Cho, 2014). Moreover, not all women who 
are informed about the details of prenatal aneuploidy tests demonstrate complete knowledge of 
the risks, benefits, and limitations of testing (Rachel Farrell, Hawkins, Barragan, Hudgins, & 
Taylor, 2015; Lewis, Hill, Skirton, & Chitty, 2016; Piechan et al., 2016). Informed consent may 
also be limited by provider knowledge and attitudes. Some general practitioners and obstetricians 
have indicated that they would offer termination of a pregnancy following positive NIPS, 
suggesting that not all providers understand the limitations of the test (Chan, Johnson, Wilson, & 
Metcalfe, 2018). Likewise, some maternal-fetal-medicine fellows have indicated that they are 
uncomfortable ordering aneuploidy screening (Swaney, Hardisty, Sayres, Wiegand, & Vora, 
2015). Furthermore, studies examining obstetricians’ experiences with prenatal aneuploidy 
screening have revealed that providers struggle with the limited time available to adequately 
counsel patients about options for prenatal screening, and that not all obstetricians provide pre-
test counseling or refer patients to genetics (R. M. Farrell, Agatisa, Mercer, Mitchum, & 
Coleridge, 2016; Gammon, Kraft, Michie, & Allyse, 2016). 
Purpose of the Study 
Only a few studies to date have examined the informed consent process for women 
undergoing routine aneuploidy screening from an obstetrician or other non-genetics medical 
provider. We developed a survey to gather information regarding what women recall of the 
informed consent process and the benefits, risks, and limitations of prenatal aneuploidy screening 
when offered as a part of their prenatal care by an obstetrician or other non-genetics medical 
provider. The purpose of this study was to assess the effectiveness of current practice in helping 
women make informed decisions about prenatal screening. 
Methods 
Participants and Procedures 
Ethical approval was obtained from the Sarah Lawrence College Institutional Review 
Board. To avoid institutional bias, participants were recruited through social media including 
Facebook groups, online forums, and Twitter for mothers and not through providers or health 
care networks. For the purpose of the study, only women who were in their third trimester of 
pregnancy or had given birth within 12 months of completing the survey were included in the 
analysis. All data were collected between December 2018 and February 2019. 
Instrumentation 
An online survey was administered through SurveyMonkey to obtain information 
regarding women’s experiences with prenatal aneuploidy testing offered to them in their current 
or most recent pregnancy. At the start of the survey, participants were informed that the study 
was voluntary and they could discontinue the survey at any time. The survey primarily consisted 
of multiple-choice questions with one free-response question. The survey was grouped into three 
categories that assessed demographics, prenatal care experiences, and knowledge of prenatal 
aneuploidy testing.  
In the demographic section, participants were asked to provide information regarding 
their age at birth at the time of their current or most recent pregnancy, ethnicity, annual 
household income, primary language spoken at home, and education level. The prenatal care 
section consisted of questions regarding whether the participant had any children prior to the 
study, if the participant had seen a prenatal genetic counselor during this or any past pregnancy, 
the type of provider (if any) that discussed prenatal aneuploidy testing with them, the types of 
prenatal tests that were offered, time spent discussing the tests, and prenatal test decision-
making. A free-response question asked for any additional comments regarding their experience.  
The final section consisted of eight multiple-response questions that tested participants’ 
knowledge of the benefits and limitations of prenatal screening, diagnostic testing, and 
ultrasound. Participants were asked which of the prenatal tests could provide specific 
information on the fetus, such as the ability to detect aneuploidy, to diagnose aneuploidy, or to 
guarantee a healthy baby. There were 8 possible answer choices: First-trimester serum screen, 
quad serum screen, NIPS, ultrasound, amniocentesis, CVS, none of these, and I don’t know. To 
create a knowledge score, one point was awarded for each correct answer chosen, one point was 
deducted for each incorrect answer chosen, and zero points were awarded or deducted if the 
choice was left blank. Participants that received negative points were adjusted to zero. Because 
each quiz question had a different number of correct answers, the questions were normalized so 
that each question held equal weight in the final score. This was done by dividing the 
participants total points by the number of correct answers for each question and multiplying this 
value by 10. The scores for each question were then summed, divided by the 80 total points, and 
multiplied by 100 to provide the participant’s knowledge score. 
Participants were also given the option to provide contact information if they wished to 
enter a raffle for one of five $100 Amazon gift cards. The survey was piloted with one eligible 
participant whose response was not included in the data analysis. Based on feedback from the 
pilot, the wording of the survey was revised to minimize confusion. 
Data Analysis 
All data was de-identified at the start of analysis. A total of 349 survey responses were 
received. Of those responses, 167 were either incomplete or did not meet eligibility criteria based 
on the timing of their pregnancy, resulting in a total of 182 eligible responses. For the remaining 
182 responses, knowledge scores were calculated and survey data was coded. All statistical 
analyses were performed using SPSS.  
One-way ANOVAs were performed to compare knowledge scores to the amount of 
education received (0-5 mins, 5-15 mins, 15+ mins) and types of testing offered (screening, 
diagnostic, both, none). Independent t-tests were performed to compare knowledge scores with 
advanced maternal age (AMA) status, previous children prior to the study, prior experience with 
a prenatal genetic counselor, provider type (genetic, non-genetic), and how recently the 
participant saw a provider based on eligibility criteria (currently pregnant, given birth). For all 
statistical analyses, a significance threshold was set at p <0.05. 
In addition to statistical analyses, a qualitative analysis was performed to evaluate an 
open-ended question that asked about further comments relating to participants’ prenatal genetic 
testing experience. Of the 182 participants, 42 women provided a response in this section. Four 
project investigators independently reviewed these responses, and common themes were 
identified and discussed.  This process generated a list of common themes. The project 
investigators then individually coded participants’ responses. The team compared the coded 
responses, discussed discrepancies, and developed rules to make coding consistent, after which 
the codes were finalized. Disagreements were addressed through conversations until the coders 
reached consensus. A consensus was met when a minimum of three of the four coders 
investigators were in agreement. Using the final codes, percentages for each theme were 
calculated. 
Results 
The study had 182 eligible participants. Participant demographics are summarized in 
Table I. A majority of participants identified as Caucasian or white (61.5%, n=112), used English 
as a primary language (92.9%, n=169), had a family household income of at least $75,000 
(68.1%, n=124), and had a college or university degree or higher (85.2%, n=155). At the time of 
surveying, 45 participants were in the third trimester (24.7%) while 137 participants had given 
birth within the last 12 months (75.3%). Participants ranged between 18-47 years old, with an 
average age of 32.5 years.   
Information regarding participants’ prenatal history can be found in Table II. Of the 174 
women who reported their age, the majority of participants were under the age of 35 (65.7%, 
n=115).  Similarly, of the 182 eligible participants, most did not have any prior children (52.7%, 
n=96). Some participants noted that they had met with a prenatal genetic counselor at some point 
in the past, prior to their current or most recent pregnancy (31.3%, n=57). Most participants 
noted that the primary person providing information to them about prenatal genetic testing for 
their current pregnancy was an obstetrician (56.6%, n=103). Other providers discussing prenatal 
testing options included a midwife (13.7%, n=25), genetic counselor (9.9%, n=18), and 
physician’s assistant or nurse (7.1%, n=13). When asked about how much time providers spent 
educating participants about prenatal aneuploidy tests, the most common answers were “between 
5 and 15 minutes” (48.9%, n=89), followed by “less than two minutes” (30.2%, n=55), and 
“fifteen to thirty minutes” (11.0%, n=20). Of note, 39 participants (35%) who reported 
obstetrician as their main provider (n= 103) spent less than two minutes in this discussion. 
A summary of the topics discussed and prenatal aneuploidy tests offered by the providers 
is in Table III. A majority of women recall that they were offered first-trimester serum screen 
(58.2%, n=106) and non-invasive prenatal screen (58.8%, n=107). Only a small portion of the 
participants report that they were offered diagnostic procedures (amniocentesis, 17.0%, n=31; 
CVS, 11.5%, n=21). However, 13.2% of women don’t recall what they were offered (n=24). 
Participants indicated that, when describing testing, most providers addressed what the test can 
detect (86.2%, n=150) but less than half addressed what the test cannot detect (44.8%, n=78). 
Less than half of the women reported that methodology (47.7%, n=83), detection rates (40.8%, 
n=71), or physical risks to the pregnancy (37.9%, n=66) were discussed when the tests were 
offered. Additionally, women’s testing preferences and personal beliefs were generally not 
addressed during the discussion (28.7%, n=50). 
The participants’ testing uptake and factors influencing their decisions are also 
summarized in Table III. Of the participants who were offered specific aneuploidy testing, most 
women report that they chose to have first-trimester screen (72.6%, n=77), quad serum screen 
(67.7%, n=42), and NIPS (78.5%, n=84). Women were less likely to report having diagnostic 
procedures, such as amniocentesis (25.8%, n=8) or CVS (9.5%, n=2). Approximately one in 
seven participants declined testing (14.4%, n=25) and approximately one in nine couldn’t recall 
the type of testing they had chosen (11.5%, n=20). 
Of the 174 women that were offered any aneuploidy testing, most of the participants 
indicated that their desire to learn more about the health of their baby influenced their decision 
on testing (67.8%, n=118). Less commonly, costs (25.9%, n=45), physical risks (24.1%, n=42) , 
and personal beliefs about testing (16.1%, n=28) were considered. The ability to identify the sex 
of the fetus influenced testing uptake in 20.7% of the women (n=36). A third of the participants 
pursued testing because their provider recommended it (32.2%, n=56). 
Participants’ responses to individual quiz questions can be found in Table IV. For most 
questions, less than half of the participants answered the question correctly. Only for three 
questions did over half of the participants select a correct answer: that “ultrasound can detect the 
sex of the baby” (72.5%, n=132), that “there is a risk for miscarriage associated with 
amniocentesis” (70.3%, n=128), and that “no test is able to determine that a baby will be born 
healthy” (64.3%, n=117). 
Overall knowledge scores for participants ranged from 0 to 82.9, with an average score of 
32.8 (SD = 21.9). The relationship between knowledge scores and a variety of participant 
variables can be found in Table V. Participants that were or would be at least 35 years old at the 
time of their delivery had significantly higher knowledge scores compared to younger women 
(p<0.001). Similarly, women with previous pregnancies had significantly higher knowledge 
scores compared to women who were pregnant or had given birth for the first time (p=0.006). 
Provider type also influenced knowledge scores. Participants that had met with a prenatal genetic 
counselor during previous pregnancies, and participants that met with a genetics specialist to 
discuss prenatal aneuploidy testing for their current or recent pregnancy, had significantly higher 
knowledge scores compared to those who did not, or those that met with a non-genetics 
specialist, respectively (p<0.001, p=0.008). Women who reported getting more time to discuss 
aneuploidy tests with providers tended to have higher knowledge scores, but this was not 
statistically significant (p=0.056). There was also a significant difference in knowledge scores 
related to the type of testing that was offered according to their reports, with women offered both 
screening and diagnostic testing scoring the highest (p=0.011). There was no significant 
difference in scores between women who were currently pregnant and those that gave birth 
within the past 12 months (p=0.919). 
Of the 182 participants that were eligible for the study, 42 women provided additional 
comments about their prenatal testing experience. Common themes in participants’ open-ended 
responses can be found in Table VI. The most common themes reflected experiences with 
providers. Some participants expressed a positive experience (14.3%, n=6), but more participants 
expressed a negative experience with providers (38.1%, n=16). Negative experiences with 
providers were further broken down into specific provider limitations including: incomplete 
patient education (19.0%, n=8), absence of informed consent (9.5%, n=4), directive providers 
(7.1%, n=3), and lack of provider knowledge (7.1%, n=3). 
 In addition, participants also addressed specific factors influencing uptake of testing 
including insurance coverage and cost of testing (28.6%, n=12) and limitations of testing (21.4%, 
n=9). Other comments indicated specific participant characteristics that respondents identified as 
relevant in their choice of testing, most commonly being information-seeking (26.2%, n=11) or 
deliberative (14.3%, n=6). Under the theme of ‘experience with testing’, participants were 
equally likely to report a positive experience (9.5%, n=4) as they were to report a negative 
experience with testing (9.5%, n=4). Additionally, an identical number of participants indicated 
that testing was not necessary (9.5%, n=4). 
Discussion 
As prenatal aneuploidy testing is becoming routine in the clinical setting, there is an 
increasing need to assess women’s understanding of the benefits, risks, and limitations of 
aneuploidy testing. To our knowledge, no study to date has examined the informed consent 
process for women undergoing routine aneuploidy testing from an obstetrician or other non-
genetics medical provider. This study offers an understanding of what women recall from their 
prenatal aneuploidy testing experience and helps assess the effectiveness of current practice in 
helping women make informed decisions about prenatal testing. 
Summary of findings  
Our study suggests that most women are limited in their understanding of the details of 
prenatal aneuploidy testing, as evidenced by low knowledge scores. The participants’ average 
knowledge score was 32.8 out of 100 (SD = 21.9). With the exception of three answers, less than 
half of the participants selected the correct response for each question (Table IV). In addition, for 
each question, multiple women indicated that they did not know the answer. This suggests that 
women making reproductive health decisions are inadequately informed about prenatal 
aneuploidy testing. Our findings support previous studies showing that women undergo testing 
with a limited understanding of why they are being tested, what they are being tested for, and 
what the tests can tell them (Johnston, Farrell, & Parens, 2017; Parham, Michie, & Allyse, 2017). 
 Participants’ poor knowledge scores are likely associated with limitations in the prenatal 
informed consent process. Professional organizations, including ACOG, recommend that all 
women are offered the option of prenatal aneuploidy testing. Despite this recommendation, 4.4% 
of women reported they were not offered prenatal aneuploidy testing (Rose & Mercer, 2016). 
While a small percentage, this is not an insignificant number if applied to the general population 
of pregnant women. Moreover, a major challenge of the informed consent process is providing 
women with enough information to make an informed decision on which testing, if any, is right 
for them. This study indicates that providers do not always spend adequate amounts of time 
discussing prenatal aneuploidy testing. Over 1/3 (n=67) of participants reported that providers 
spent a maximum of five minutes discussing aneuploidy testing. More specifically, 39 
participants recalled that their obstetrician spent less than two minutes in this discussion, of 
particular significance since the obstetrician is the most frequent provider of information on 
aneuploidy testing (n=103) reported in this study.  It is difficult to comprehend how women can 
receive adequate information and exercise informed consent for a complex decision in such a 
short amount of time. 
Furthermore, a majority of women reported that providers did not address what the tests 
can’t detect, testing methodology, detection rates, or physical risks to the pregnancy. This lack of 
discussion was reiterated in close to 1/5 of participants’ open-ended responses. This includes the 
comments that “most of what I marked in previous questions as ‘provider discussed with me’ 
was due to my and my husband’s questions”, “I wish things had been explained more clear 
regarding dangers and what the tests actually entailed”, and “I wish I was given more 
information on the topic from the doctor rather than having to read about it”. Allotting sufficient 
time for a comprehensive discussion on testing may increase women’s knowledge of testing. 
The participants who met with a non-genetics provider had a significantly lower 
knowledge score compared to the participants who met with a genetics specialist.  The 
inadequate patient understanding about prenatal screening and testing options may be due in part 
to lack of provider knowledge about prenatal genetic screening. Findings concluded that 7.1% of 
participants felt their providers lacked knowledge. This thought was echoed by one participant 
who stated that “The midwife I spoke to was very poorly informed.” Non-genetic providers may 
offer screening options during patient visits, but the lack of in-depth discussion or knowledge on 
the providers side raises the issue that patients may not be receiving adequate knowledge needed 
for informed consent. In previous studies on providers, 45% of obstetricians indicated that their 
residency training in this prenatal counseling was inadequate to nonexistent, and a third of the 
physicians use information provided by commercial laboratories as initial source to acquire 
knowledge about NIPT (Cleary-Goldman et al., 2006; R. M. Farrell et al., 2016). Genetic 
providers are well-versed in testing details, and prior studies have shown that genetic counseling 
was found to positively correlate with sufficient knowledge regarding genetic testing (Sheinis, 
Bensimon, & Selk, 2017).  
 In this study, some maternal factors were determined to significantly influence women’s 
knowledge in prenatal testing, including maternal age and number of children. Maternal age 
plays a significant role in prenatal care as women who are 35 and older are considered high-risk 
for having a child with aneuploidy (Driscoll & Gross, 2009). Although individual institutions 
differ in practice, these women are more likely to receive additional care, such as a referral to 
meet with a genetic counselor, additional ultrasound and obstetric monitoring, and screening and 
diagnostic tests for aneuploidy (Johnson et al., 2012). The high-risk status and the differential 
treatment from healthcare providers may result in their higher knowledge scores compared to 
women who are younger with lower risks. Additionally, women who have had previous 
pregnancies prior to this study, scored higher than first-time mothers. This suggests that women 
who have been pregnant in the past may benefit from the reiteration of the prenatal care process.  
Another focus of our study was to investigate participants’ choices in prenatal aneuploidy 
testing. More than half of participants indicated that their desire to learn more about the health of 
their baby influenced their decision on testing. This result suggests that the health of the baby is a 
driving factor for women when making a decision about prenatal testing. Other less factors 
influencing participants’ decision on testing include costs: risks associated with testing, 
limitations of testing, and the desire to learn more about the sex of the baby. Not all women 
valued the same information, and this highlights the need for a complete informed consent. 
Nevertheless, close to 1 in 10 participants that responded to the open-ended question indicated 
that they did not receive informed consent for testing. Women expressed “The test was being 
performed without asking me”, “I think I had the serum screening but it was never really 
discussed with me so I'm not 100% sure”, and “I asked when I would be having the testing for 
Down syndrome... It was noted to me that it already had been performed, and all was normal. 
Therefore, I do not recall how the genetic testing was done”. These results are consistent with 
studies that found that obstetrical providers are less likely to believe that informed consent 
should be obtained prior to NIPS (Ruth Farrell, Mercer, Agatisa, Smith, & Philipson, 2014; 
Silcock, Liao, Hill, & Chitty, 2015; van den Heuvel et al., 2010). 
Another component of informed consent is considering patient preferences for testing; 
yet, a vast majority of providers did not discuss beliefs and preferences about whether or not 
testing was right for the patients (71.3%, n=124). Similarly, close to ⅓ of women indicated that 
their decision to pursue prenatal aneuploidy testing was influenced by provider’s 
recommendations, suggesting that some providers are directive in their counseling approach.  
This was further emphasized in the open-ended comments. One woman reflected that her 
medical providers “were pushing for amnio”. Another woman commented that she “took the test 
because [her] provider provided [it] as a non-option test”. These findings are consistent with a 
study that observed that physicians were less consistent in the practice of non-directiveness 
relative to genetic counselors, which was thought to be caused by an inherent bias in what they 
believe is best for their patients (Botkin, 1990). Together, these findings indicate that the 
requirement for informed decision-making is generally not being met in clinical practice. In the 
select cases where participants were given the opportunity to make an informed decision, 
participants’ open-ended responses  reflected positive experiences with providers: “I am very 
grateful to have been presented with options for different types of genetic testing, especially 
since there were some results which were unfavorable” and “I appreciate that my health care 
provider did not try to influence my decision to forego first trimester testing”. 
Study Limitations 
As with many quantitative research surveys which rely on volunteer participants, the 182 
eligible individuals who elected to participate in our study may not have been representative of 
all mothers; for example, they may have had a particular interest in prenatal screening. Our 
results could have also been skewed if participants were compelled to take the survey due to 
either an unusually positive or negative experience with our topic, which may also have 
influenced their survey responses. Our participant demographics also show a skew towards 
Caucasian women (61.5%) and women who are educated (45.2% completed at least a university 
or college degree). Furthermore, the internet was also used for the means of survey distribution, 
which allowed us to succeed in recruiting respondents from a broader geographic region. 
However, even so, our results overrepresent the east coast. This may have also marginalized 
mothers who are less inclined to use social media. 
Research Recommendations 
Our study was designed to investigate patient memory retention and understanding of 
prenatal testing options. The administration of a survey on this topic directly following an 
appointment with a provider may offer a clearer picture of what new and expectant mothers are 
being told about their screening options. In addition, further surveying of providers may provide 
a more complete understanding of patient education and informed consent in prenatal settings. 
Our study suggests a lack of informed consent in the realm of prenatal screening that patient 
education guidelines may help to close and further investigations in this area may be warranted. 
Practice Implications  
The diverse number of prenatal screening and testing options has changed the practice of 
prenatal care. The differences in test characteristics should be made clear to both provider and 
patients. A goal of genetic counseling is to support informed and autonomous decision making in 
order to improve patient outcomes. Comprehensive training from non-genetic professionals in 
aspects of this practice along with the specifications of prenatal genetics may aid in informed 
decisions about prenatal testing from a patient standpoint. The implementation of standard 
consenting protocols and decision aids about screening and testing options may increase 
knowledge and satisfaction of both the patient and provider. Educational tools and patient-
friendly consent forms could allow patients to understand the specifics of testing and enable 
them to make an informed decision about their pregnancy care.  
 
Conclusions 
During the course of their pregnancy, some women are confronted with a complex and 
ever-changing array of prenatal testing options. Striving for informed consent with prenatal 
testing improves the likelihood that patient decisions are made with sufficient knowledge and 
understanding, and are consistent with the patient’s values and attitudes. However, our data 
indicates that, with no patient education guidelines in place, the quality and quantity of their 
informed consent process may vary greatly. This study also found that meeting with a trained 
genetic professional, AMA status, as well as having both screening and diagnostic options, 
maximize patient understanding and retention of genetic testing information. Though further 
analysis remains to be done on how to yield higher levels of patient knowledge, our study 
demonstrates that, under current practice, a significant percentage of women are not given the 
opportunity to make their own decisions in regards to their prenatal healthcare. As the prenatal 
testing choices available to women increase, ensuring healthcare providers are adept at educating 
women on the benefits and limitations of the myriad screening and diagnostic options available 
to them is critical. 
In recent years, the rapid incorporation of aneuploidy testing in routine prenatal care has 
threatened the ability of women to make autonomous decisions. This emerging practice rests on 
the assumption that having prenatal tests is a woman’s preferred choice, and therefore that 
offering them the opportunity to make a choice is unnecessary, thus undermining women’s 
reproductive autonomy (Kater-Kuipers, de Beaufort, Galjaard, & Bunnik, 2018). As seen in this 
study, when given the choice, 14.4% of women did not have testing done. The issue of 
routinization and lack of informed consent may in turn, trivialize more difficult and controversial 
topics such as the choice of doing invasive testing, termination of pregnancy, and disability 
(Kater-Kuipers et al., 2018). As one of our participants stated, “just because we can do hundreds 
of tests does not mean that we should do them.” 
 
 
All procedures followed were in accordance with the ethical standards of the responsible 
committee on human experimentation (institutional and national) and with the Helsinki 
Declaration of 1975, as revised in 2000 (5). Informed consent was obtained from all patients for 
being included in the study. 
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Table I. Participant demographics 
    n (%) 
Ethnicity African American or Black 5 (2.7%) 
 Asian or Asian American 33 (18.1%) 
 Caucasian or White 112 (61.5%) 
 Hispanic or Latino 8 (4.4%) 
 Jewish 3 (1.6%) 
 Native American or Alaska Native 1 (0.5%) 
 Mixed 20 (11.0%) 
Primary Language Chinese 9 (4.9%) 
 English 169 (92.9%) 
 Spanish 3 (1.6%) 
 Yiddish 1 (0.5%) 
Family Income Under $15,000 4 (2.2%) 
 Between $15,000 and $29,999 9 (4.9%) 
 Between $30,000 and $49,999 14 (7.7%) 
 Between $50,000 and $74,999 31 (17.0%) 
 Between $75,000 and $99,999 36 (19.8%) 
 Between $100,000 and $150,000 39 (21.4%) 
 Over $150,000 49 (26.9%) 
Education Level Some high school 1 (0.5%) 
 High school graduate, diploma, or equivalent 10 (5.5%) 
 Technical or Associates degree 3 (1.6%) 
 Some college 13 (7.1%) 
 College or university degree 81 (44.5%) 
  Graduate degree 74 (40.7%) 
 
  
Table II. Participants’ prenatal history 
    n (%) 
Advanced Maternal Age Status <35 years 115 (65.7%) 
 ≥35 years 60 (34.3%) 
Number of Children 0 96 (52.7%) 
 1 62 (34.1%) 
 2 16 (8.8%) 
 3 or more 8 (4.4%) 
Previously Met with a Prenatal Genetic Counselor Yes 57 (31.3%) 
 No 125 (68.7%) 
Provider Type Obstetrician 103 (56.6%) 
 Midwife 25 (13.7%) 
 Genetic counselor 18 (9.9%) 
 Physician’s assistant/nurse 13 (7.1%) 
 Maternal-fetal medicine specialist 6 (3.3%) 
 Family doctor/general practitioner 6 (3.3%) 
 Fertility doctor 5 (2.7%) 
 Other 5 (2.7%) 
 Geneticist 1 (0.5%) 
Time Spent Educating No time 9 (4.9%) 
 Less than 2 minutes 55 (30.2%) 
 Between 2 and 5 minutes 3 (1.6%) 
 5 to 15 minutes 89 (48.9%) 
 15 to 30 minutes 20 (11.0%) 
  More than 30 minutes 6 (3.3%) 
 
  
Table III. Provider’s practice and factors influencing uptake 
    n (%) 
Testing Offered First trimester serum screen 106 (58.2%) 
 Quad serum screen  62 (34.1%) 
 Non-invasive prenatal screen (NIPS)  107 (58.8%) 
 Amniocentesis  31 (17.0%) 
 Chorionic Villus Sampling (CVS)  21 (11.5%) 
 None  8 (4.4%) 
 I do not recall what I was offered  24 (13.2%) 
Points Addressed About Testing What testing can detect 150 (86.2%) 
 What testing cannot detect 78 (44.8%) 
 Technology and methodology of how the tests are performed 83 (47.7%) 
 Physical risks to the pregnancy 66 (37.9%) 
 Beliefs and preferences about whether testing is right for you 50 (28.7%) 
 Detection rates, false positives, false negatives 71 (40.8%) 
 Interpretation of possible results 59 (33.9%) 
 What to do after getting your results 47 (27.0%) 
 Provider did not talk about the test 11 (6.3%) 
Uptake of Testing* First trimester serum screen  77 (72.6%) 
 Quad serum screen  42 (67.7%) 
 Non-invasive prenatal screen (NIPS)  84 (78.5%) 
 Amniocentesis  8 (25.8%) 
 Chorionic Villus Sampling (CVS)  2 (9.5%) 
 I had genetic testing, but I'm not sure what type 20 (11.5%) 
 I am not sure if I had genetic testing during my pregnancy 6 (3.4%) 
 I did not have any testing done 25 (14.4%) 
Factors Influencing Uptake* Cost of testing  45 (25.9%) 
 Desire to learn more about the health of the baby  118 (67.8%) 
 Desire to learn the sex of the baby  36 (20.7%) 
 Beliefs regarding genetic testing  28 (16.1%) 
 Risks of testing  42 (24.1%) 
 Because my healthcare provider recommended it 56 (32.2%) 
 Because I had it done during my last pregnancy 26 (14.9%) 
  Pressure from family/friends/community  5 (2.9%) 
* percentages reflect only those who were offered testing 
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Table V. Participant knowledge scores between different variables 
    
Knowledge score 
(average ± SD) 
p-value 
Advanced Maternal Age Status <35 years 29.0 ± 21.3 <0.001* 
 ≥35 years 41.2 ± 20.9  
Number of Children 0 28.6 ± 21.7 0.006* 
 1+ 37.5 ± 21.3  
Previously Met with a Prenatal Genetic Counselor Yes 50.6 ± 21.3 <0.001* 
 No 28.8 ± 21.2  
Provider Type Genetics Provider 45.3 ± 22.8 0.008* 
 Non- Genetics Provider 31.3 ± 21.4  
Time Spent Educating 0-5 mins 28.3 ± 19.4 0.056 
 5 to 15 minutes 34.2 ± 22.4  
 15 or more minutes 39.5 ± 24.5  
Aneuploidy Testing Offered None 18.0 ± 14.9 0.011* 
 Screening  34.8 ± 20.9  
 Diagnostic Testing 31.9 ± 8.20  
 Both 44.3 ± 22.4  
Eligibility Criteria Third Trimester 32.5 ± 21.3 0.919 
  Gave Birth in Past 12 Months 32.9 ± 22.2   
* statistically significant at p < 0.05.    
 
  
Table VI. Participants’ responses to open-ended question 
    n (%) Examples 
Provider experience Positive experience 6 (14.3%) "genetic counselors were very helpful" 
 Negative experience 16 (38.1%) "I wish I was given more information on the 
topic from the doctor rather than having to 
read about it" 
 Incomplete patient education 8 (19.0%) "I wish things had been explained more clear 
regarding dangers and what the tests actually 
entailed" 
 No informed consent 4 (9.5%) "the test was being performed without asking 
me" 
 Directive provider 3 (7.1%) "they were pushing for amnio" 
 Lack of provider knowledge  3 (7.1%) "the midwife I spoke to was very poorly 
informed" 
Factors influencing testing Insurance coverage/ cost  12 (28.6%) "wish insurance provided coverage for more 
testing" 
 
Testing limitations 9 (21.4%) "I had lost a twin, so that prevented me from 
receiving accurate results" 
Participant characteristics Information seeking 11 (26.2%) "I wanted to be as prepared as possible" 
 
Deliberating testing options 6 (14.3%) "I was very glad to have pursued 
amniocentesis with this pregnancy, though 
the decision was not easy- due to the risk, 
however small, of miscarriage...The NIPT test 
is great but there is still that fear of a false 
negative" 
Testing experience Positive experience 4 (9.5%) "I was very pleased this was an option for me" 
 
Negative experience 4 (9.5%) "after getting tested, my son was still born 
with a chromosomal defect" 
  Beliefs that testing was not 
necessary 
4 (9.5%) "I declined all optional tests as I did not see 
the relevance to my personal situation" 
 
 
 
